Topical vaccination: The skin as a unique portal to adaptive immune responses

Seminars in Immunopathology

Volumn 29, Issue 1, 2007, Pages 71-80

  Huang, Chun Ming ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Skin immunity; Stratum corneum; Surfactants; Topical vaccination

Indexed keywords

CHOLERA TOXIN; DNA VACCINE; ENTEROTOXIN; GAMMA INTERFERON; HEPATITIS B SURFACE ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 1ALPHA; TUMOR NECROSIS FACTOR ALPHA; VACCINE; SURFACTANT;

ADAPTIVE IMMUNITY; CELL MIGRATION; CELL PROLIFERATION; IMMUNOGENICITY; IMMUNOMODULATION; KERATINOCYTE; LANGERHANS CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN; SKIN PENETRATION; STRATUM CORNEUM; T LYMPHOCYTE; ANIMAL; DRUG EFFECT; HUMAN; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; METHODOLOGY; SKIN ABSORPTION; VACCINATION;

ADMINISTRATION, CUTANEOUS; ANIMALS; HUMANS; SKIN; SKIN ABSORPTION; SURFACE-ACTIVE AGENTS; VACCINATION;

EID: 34748898401     PISSN: 18632297     EISSN: 18632300     Source Type: Journal    
DOI: 10.1007/s00281-007-0059-2     Document Type: Review

References (77)

1. Belyakov IM, Hammond SA, Ahlers JD et al (2004) Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J Clin Invest 113:998-1007
2. Donnelly JJ, Ulmer JB (1999) DNA vaccines for viral diseases. Braz J Med Biol Res 32:215-222
3. Huang CM, Wang CC, Kawai M et al (2006) Surfactant sodium lauryl sulfate enhances skin vaccination: molecular characterization via a novel technique using ultrafiltration capillaries and mass spectrometric proteomics. Mol Cell Proteomics 5:523-532
4. Huang CM, Shi Z, DeSilva TS et al (2005) A differential proteome in tumors suppressed by an adenovirus-based skin patch vaccine encoding human carcinoembryonic antigen. Proteomics 5:1013-1023
5. Huang CM, Xu H, Wang CC et al (2005) Proteomic characterization of skin and epidermis in response to environmental agents. Expert Rev Proteomics 2:809-820
6. Lore K, Sonnerborg A, Spetz AL et al (1998) Erratum to "Immunocytochemical detection of cytokines and chemokines in Langerhans cells and in vitro derived dendritic cells". J Immunol Methods 218:173-187
7. Peachman KK, Rao M, Alving CR (2003) Immunization with DNA through the skin. Methods 31:232-242
8. Tang DC, Shi Z, Curiel DT (1997) Vaccination onto bare skin. Nature 388:729-730
9. Takahashi H (2006) [New aspect of immune system: innate immunity and acquired immunity]. Kansenshogaku Zasshi 80:463-468
10. Valladeau J, Saeland S (2005) Cutaneous dendritic cells. Semin Immunol 17:273-283
11. Van Kampen KR, Shi Z, Gao P et al (2005) Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 23:1029-1036
12. Albanesi C, Scarponi C, Giustizieri ML et al (2005) Keratinocytes in inflammatory skin diseases. Curr Drug Targets Inflamm Allergy 4:329-334
13. Moelling K (1997) DNA for genetic vaccination and therapy. Cytokines Cell Mol Ther 3:127-135
14. Chen D, Maa YF, Haynes JR (2002) Needle-free epidermal powder immunization. Expert Rev Vaccines 1:265-276
15. Choi MJ, Kim JH, Maibach HI (2006) Topical DNA vaccination with DNA/Lipid based complex. Curr Drug Deliv 3:37-45
16. Cui Z, Dierling A, Foldvari M (2006) Non-invasive immunization on the skin using DNA vaccine. Curr Drug Deliv 3:29-35
17. Coronato S, Laguens GE, Spinelli OM et al (1998) [Dendritic cells and their role in pathology]. Medicina (B Aires) 58:209-218
18. Kondo S (1999) The roles of keratinocyte-derived cytokines in the epidermis and their possible responses to UVA-irradiation. J Investig Dermatol Symp Proc 4:177-183
19. Shi Z, Zeng M, Yang G et al (2001) Protection against tetanus by needle-free inoculation of adenovirus-vectored nasal and epicutaneous vaccines. J Virol 75:11474-11482
20. Sasaki S, Takeshita F, Xin KQ et al (2003) Adjuvant formulations and delivery systems for DNA vaccines. Methods 31:243-254
21. Glenn GM, Scharton-Kersten T, Vassell R et al (1998) Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. J Immunol 161:3211-3214
22. Glenn GM, Rao M, Matyas GR et al (1998) Skin immunization made possible by cholera toxin. Nature 391:851
23. Glenn GM, Scharton-Kersten T, Vassell R et al (1999) Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants. Infect Immun 67:1100-1106
24. Yu J, Cassels F, Scharton-Kersten T et al (2002) Transcutaneous immunization using colonization factor and heat-labile enterotoxin induces correlates of protective immunity for enterotoxigenic Escherichia coli. Infect Immun 70:1056-1068
25. Tamura SI, Kurata T (2000) A proposal for safety standards for human use of cholera toxin (or Escherichia coli heat-labile enterotoxin) derivatives as an adjuvant of nasal inactivated influenza vaccine. Jpn J Infect Dis 53:98-106
26. Frech SA, Kenney RT, Spyr CA et al (2005) Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch. Vaccine 23:946-950
27. Hammond SA, Walwender D, Alving CR et al (2001) Transcutaneous immunization: T cell responses and boosting of existing immunity. Vaccine 19:2701-2707
28. Matyas GR, Friedlander AM, Glenn GM et al (2004) Needle-free skin patch vaccination method for anthrax. Infect Immun 72:1181-1183
29. Tamura SI, Kurata T (2000) A proposal for safety standards for human use of cholera toxin (or Escherichia coli heat-labile enterotoxin) derivatives as an adjuvant of nasal inactivated influenza vaccine. Jpn J Infect Dis 53:98-106
30. Beignon AS, Briand JP, Rappuoli R et al (2002) The LTR72 mutant of heat-labile enterotoxin of Escherichia coli enhances the ability of peptide antigens to elicit CD4(+) T cells and secrete gamma interferon after coapplication onto bare skin. Infect Immun 70:3012-3019
31. Dean HJ (2005) Epidermal delivery of protein and DNA vaccines. Expert Opin Drug Deliv 2:227-236
32. Niess JH, Brand S, Gu X et al (2005) CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science 307:254-258
33. Partidos CD, Beignon AS, Briand JP et al (2004) Modulation of immune responses with transcutaneously deliverable adjuvants. Vaccine 22:2385-2390
34. Robbins JB, Schneerson R, Szu SC (1995) Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis 171:1387-1398
35. Tirlapur UK, Mulholland WJ, Bellhouse BJ et al (2006) Femtosecond two-photon high-resolution 3D imaging, spatial-volume rendering and microspectral characterization of immunolocalized MHC-II and mLangerin/CD207 antigens in the mouse epidermis. Microsc Res Tech 69:767-775
36. Zhang J, Shi Z, Kong FK et al (2006) Topical application of Escherichia coli-vectored vaccine as a simple method for eliciting protective immunity. Infect Immun 74:3607-3617
37. Mulholland WJ, Arbuthnott EA, Bellhouse BJ et al (2006) Multiphoton high-resolution 3D imaging of Langerhans cells and keratinocytes in the mouse skin model adopted for epidermal powdered immunization. J Invest Dermatol 126:1541-1548
38. Chen D, Weis KF, Chu Q et al (2001) Epidermal powder immunization induces both cytotoxic T-lymphocyte and antibody responses to protein antigens of influenza and hepatitis B viruses. J Virol 75:11630-11640
39. Sasaki S, Takeshita F, Xin KQ et al (2003) Adjuvant formulations and delivery systems for DNA vaccines. Methods 31:243-254
40. Scharton-Kersten T, Yu J, Vassell R et al (2000) Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants. Infect Immun 68:5306-5313
41. Pizza M, Giuliani MM, Fontana MR et al (2001) Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 19:2534-2541
42. Ryan EJ, McNeela E, Pizza M et al (2000) Modulation of innate and acquired immune responses by Escherichia coli heat-labile toxin: distinct pro-and anti-inflammatory effects of the nontoxic AB complex and the enzyme activity. J Immunol 165:5750-5759
43. Ryan EJ, McNeela E, Murphy GA et al (1999) Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells. Infect Immun 67:6270-6280
44. Takeshita F, Gursel I, Ishii KJ et al (2004) Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9. Semin Immunol 16:17-22
45. Krieg AM (2002) CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20:709-760
46. Beignon AS, Briand JP, Muller S et al (2002) Immunization onto bare skin with synthetic peptides: immunomodulation with a CpG-containing oligodeoxynucleotide and effective priming of influenza virus-specific CD4+ T cells. Immunology 105:204-212
47. Calarota SA, Kjerrstrom A, Islam KB et al (2001) Gene combination raises broad human immunodeficiency virus-specific cytotoxicity. Hum Gene Ther 12:1623-1637
48. Stevceva L, Ferrari MG (2005) Mucosal adjuvants. Curr Pharm Des 11:801-811
49. von Hunolstein C, Mariotti S, Teloni R et al (2001) The adjuvant effect of synthetic oligodeoxynucleotide containing CpG motif converts the anti-Haemophilus influenzae type b glycoconjugates into efficient anti-polysaccharide and anti-carrier polyvalent vaccines. Vaccine 19:3058-3066
50. Ragupathi G, Livingston PO, Hood C et al (2003) Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin Cancer Res 9:5214-5220
51. Hickey DK, Bao S, Ikeda LT et al (2005) Induction of anti-chlamydial mucosal immunity by transcutaneous immunization is enhanced by topical application of GM-CSF. Curr Mol Med 5:599-605
52. Bowne WB, Wolchok JD, Hawkins WG et al (1999) Injection of DNA encoding granulocyte-macrophage colony-stimulating factor recruits dendritic cells for immune adjuvant effects. Cytokines Cell Mol Ther 5:217-225
53. Bins AD, Jorritsma A, Wolkers MC et al (2005) A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat Med 11:899-904
54. Curry JL, Qin JZ, Bonish B et al (2003) Innate immune-related receptors in normal and psoriatic skin. Arch Pathol Lab Med 127:178-186
55. Shi Z, Curiel DT, Tang DC (1999) DNA-based non-invasive vaccination onto the skin. Vaccine 17:2136-2141
56. Stevenson FK, Ottensmeier CH, Johnson P et al (2004) DNA vaccines to attack cancer. Proc Natl Acad Sci USA 101:14646-14652
57. Shen SC, Lee WR, Fang YP et al (2006) In vitro percutaneous absorption and in vivo protoporphyrin IX accumulation in skin and tumors after topical 5-aminolevulinic acid application with enhancement using an erbium:YAG laser. J Pharm Sci 95:929-938
58. Fang JY, Lee WR, Shen SC et al (2004) Transdermal delivery of macromolecules by erbium:YAG laser. J Control Release 100:75-85
59. Lee WR, Shen SC, Lai HH et al (2001) Transdermal drug delivery enhanced and controlled by erbium:YAG laser: a comparative study of lipophilic and hydrophilic drugs. J Control Release 75:155-166
60. Lee WR, Shen SC, Liu CR et al (2006) Erbium:YAG laser-mediated oligonucleotide and DNA delivery via the skin: An animal study. J Control Release 115:344-353
61. Benson HA (2006) Transfersomes for transdermal drug delivery. Expert Opin Drug Deliv 3:727-737
62. Elias PM (2005) Stratum corneum defensive functions: an integrated view. J Invest Dermatol 125:183-200
63. Godefroy S, Peyre M, Garcia N et al (2005) Effect of skin barrier disruption on immune responses to topically applied cross-reacting material, CRM(197), of diphtheria toxin. Infect Immun 73:4803-4809
64. Strid J, Hourihane J, Kimber I et al (2004) Disruption of the stratum corneum allows potent epicutaneous immunization with protein antigens resulting in a dominant systemic Th2 response. Eur J Immunol 34:2100-2109
65. Choi MJ, Maibach HI (2003) Topical vaccination of DNA antigens: topical delivery of DNA antigens. Skin Pharmacol Appl Skin Physiol 16:271-282
66. Bryan D, Walker KB, Ferguson M et al (2005) Cytokine gene expression in a murine wound healing model. Cytokine 31:429-438
67. Weinberg A, Krisanaprakornkit S, Dale BA (1998) Epithelial antimicrobial peptides: review and significance for oral applications. Crit Rev Oral Biol Med 9:399-414
68. Schmuth M, Neyer S, Rainer C et al (2002) Expression of the C-C chemokine MIP-3 alpha/CCL20 in human epidermis with impaired permeability barrier function. Exp Dermatol 11:135-142
69. Nickoloff BJ, Naidu Y (1994) Perturbation of epidermal barrier function correlates with initiation of cytokine cascade in human skin. J Am Acad Dermatol 30:535-546
70. Kirsner RS, Froelich CW (1998) Soaps and detergents: understanding their composition and effect. Ostomy/Wound Manage 44:62S-69S
71. Savic SD, Savic MM, Vesic SA et al (2006) Vehicles based on a sugar surfactant: colloidal structure and its impact on in vitro/in vivo hydrocortisone permeation. Int J Pharm 320:86-95
72. Fang JY, Hwang TL, Huang YL et al (2006) Enhancement of the transdermal delivery of catechins by liposomes incorporating anionic surfactants and ethanol. Int J Pharm 310:131-138
73. Vyas SP, Singh RP, Jain S et al (2005) Non-ionic surfactant based vesicles (niosomes) for non-invasive topical genetic immunization against hepatitis B. Int J Pharm 296:80-86
74. Gupta PN, Mishra V, Rawat A et al (2005) Non-invasive vaccine delivery in transfersomes, niosomes and liposomes: a comparative study. Int J Pharm 293:73-82
75. Fartasch M (1997) Ultrastructure of the epidermal barrier after irritation. Microsc Res Tech 37:193-199
76. Moore PN, Shiloach A, Puvvada S et al (2003) Penetration of mixed micelles into the epidermis: effect of mixing sodium dodecyl sulfate with dodecyl hexa(ethylene oxide). J Cosmet Sci 54:143-159
77. Singh M, Kazzaz J, Ugozzoli M et al (2006) Polylactide-co-glycolide microparticles with surface adsorbed antigens as vaccine delivery systems. Curr Drug Deliv 3:115-120